Taiko Pharmaceutical Co.,Ltd.
Notice Regarding Approval for Change of Market Segment to the Standard Market and Withdrawal of the Plan to Comply with Prime Market Listing Maintenance Standards
Approval has been received for the change of market segment to the Standard Market; trading will occur on the Standard Market from 2026-11-02 onward. The plan to maintain listing standards for the Prime Market has been withdrawn.
Key Figures
- Scheduled date of market segment change: 2026-11-02
- Start date of trading on the Standard Market after transition: Same day
- Plan to maintain listing standards for the Prime Market: Withdrawn
AI要約
Formal Approval of Market Segment Change and Rationale
Taiko Pharmaceutical Co.,Ltd. has received approval from the Tokyo Stock Exchange for a change of market segment to the Standard Market. The company explains that, from the perspective of long-term management strategy and maximizing shareholder value, the Standard Market is judged to be the market segment appropriate for its current business scale and growth stage. Consequently, efforts to comply with the Prime Market listing maintenance standards will not continue, and the plan has been withdrawn.
Future Schedule and Impact
The scheduled date for the market segment change is 2026-11-02, after which trading will take place on the Standard Market. No additional measures related to the transition to the Standard Market are specifically described, and the company will continue to aim to maintain and enhance shareholder value.
Taiko Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
